Brief Admission for Adolescents Who Self-harm

August 1, 2025 updated by: Sofie Westling, Region Skane

Brief Admission by Self-referral for Adolescents Who Self-harm, at Risk for Suicide. A Qualitative Study to Optimise and Standardise the Intervention

There is still no consensus on how to manage suicidal behavior in youth with recurrent self-harm at times when the risk for suicide is imminent (1). Brief Admission (BA) has evolved as a promising crisis intervention for adults with self-harm (2). The characteristics of BA is different from other types of admission, being focused on prevention through increased autonomy and self-care, based on structured and voluntary brief self-referrals to hospital (3). As a result of a randomized controlled trial, BA is since January 2019, continuously offered to adults with self-harm at risk for suicide in Skåne (4). Parallel to this clinical trial, the method has been adapted to work in a psychiatric setting for adolescents. At present 24 adolescents have access to the method in Skåne. Clinical experiences from staff are promising, however, the lived experiences have not been collected in a standardized way.

The aim of the present study is to gather information on how BA in its present, standardized form works for adolescents, their loved ones and staff working at the ward providing BA. This will be done through semi-structured interviews with:

  1. Adolescents using BA and their loved ones
  2. Staff working at the ward providing BA. Data will be analyzed with qualitative analysis (5, 6). The ultimate aim is to use these results to optimize the current standardized version of BA for adolescents in order to test in a randomized clinical trial.

Study Overview

Study Type

Observational

Enrollment (Actual)

59

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Skåne
      • Lund, Skåne, Sweden, 22185
        • Psykiatri och habilitering, Region Skåne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

13 years to 100 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Adolescents with an active BA contract, their loved ones who have given informed consent to participate and psychiatric staff working with the adolescents.

Description

Sample 1:

Inclusion Criteria:

  • Adolescents with an active BA contract
  • At least 13 years of age.
  • Able to consent to study participation through written and oral information.
  • Consent from caregivers
  • Given consent to participate

Exclusion Criteria:

  • Below the age of 13.

Sample 2:

Inclusion Criteria:

  • Parents to adolescents with an active BA contract
  • At least 18 years of age.
  • Able to consent to study participation through written and oral information.
  • Given consent to participate

Exclusion Criteria:

  • None

Sample 3:

Inclusion Criteria:

  • Staff working with adolescents with an active BA contract
  • At least 18 years of age.
  • Able to consent to study participation through written and oral information.
  • Given consent to participate

Exclusion Criteria:

  • None

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Adolescents
Adolescents with a contract for Brief admission by self-referral
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
Parents
Parents to adolescents with a contract for Brief admission by self-referral
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI
Staff
Health care providers who work with adolescents with a contract for Brief admission by self-referral
Each participant will attend a 30-60 minute semi-structured interview conducted by the CI

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Perceived effective components of Brief Admission for adolescents
Time Frame: 60mins
Qualitative data from interviews
60mins
Potential adaptations of the method to better fit adolescents
Time Frame: 60mins
Qualitative data from interviews
60mins
Areas where Brief Admission have the most prominent perceived effects in adolescents
Time Frame: 60mins
Qualitative data from interviews
60mins

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Actual)

June 30, 2025

Study Completion (Actual)

June 30, 2025

Study Registration Dates

First Submitted

July 4, 2021

First Submitted That Met QC Criteria

July 13, 2021

First Posted (Actual)

July 15, 2021

Study Record Updates

Last Update Posted (Actual)

August 6, 2025

Last Update Submitted That Met QC Criteria

August 1, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 2020-01840

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Data is qualitative, transcriptions from interviews. Even if personal identifiers are removed, it is difficult to ensure enough secrecy/privacy for the participants.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Suicide, Attempted

Clinical Trials on Semi-structured interviews

Subscribe